Corporate responsibility report puts IDEXX Laboratories (IDXX) in focus IDEXX Laboratories (IDXX) recently released its 2025 Corporate Responsibility Report, drawing attention to the stock as investors assess how the company’s plans for pet diagnostics, employees, and sustainability fit into its long term outlook. See our latest analysis for IDEXX Laboratories. The recent 6.3% 30 day share price return contrasts with IDEXX Laboratories’ share price being down 15.0% year to date, while the 3...

IDEXX Laboratories (NASDAQ:IDXX) released its 2025 Corporate Responsibility Report, outlining progress across innovation, workforce development, and environmental initiatives that support the company’s long-term growth strategy. Key Investor TakeawaysIDEXX published its 2025 Corporate Responsibility Report, highlighting advances in innovation, employee development, and sustainability.

Elanco Animal Health (ELAN) seems "best-positioned name" into the Q2 print, with IDEXX Laboratories

IDXX Laboratories heads into Q2 earnings with revenue and EPS growth expected, led by CAG diagnostics, VetLab gains and expanding software adoption.

Jensen Investment Management, an asset management company based in the US, released its second-quarter 2026 investor letter for the “Jensen Quality Growth Equity Strategy”. A copy of the letter is available to download here. The fund seeks long-term growth by investing in high-quality companies with durable competitive advantages. It returned 10.94% net of fees in […]

As data centers strain water systems, FIW, PHO, and CGW offer investors ETF-based access to water utilities, infrastructure, and equipment firms, each with distinct fees and concentration.

ISRG, IDXX and ALC are three AI-driven medical device laggards with strong business momentum and improving earnings estimates for a potential 2H rebound.

IDEXX Laboratories will release its second-quarter earnings next month, and analysts anticipate a single-digit bottom-line growth.